btsnavbar.jpg


Ex Vivo Metrics™: How Drug Studies in Reanimated Human Organs Could Revitalize the Drug Development Process

An editorial by Gerald Curtis, PhD

Fallout from the catastrophic phase I clinical trial of TeGenero’s monoclonal antibody TGN1412 in March 2006,1 in which 6 volunteers suffered life-threatening “cytokine storms,” includes newly tightened regulations in the United Kingdom and renewed concern worldwide about first-in-human trials, particularly for compounds with novel targets or mechanisms of action. 

Read more  -  More Editorials

DNA Genotyping from human FFPE Samples

In this feasibility study, Applied Biosystems demonstrates how the combined 
use Recover All Total Nucleic

Acid Isolation Kit and TaqMan SNP Genotyping 
Assay can result in high quality, reproducible, and reliable genotyping 
data..  Read more
Millipore has launched the CellCiphr Cytotoxicity Profiling Assay Kit using human HepG2 cells. This assay panel detects drug-induced hepatotoxicity and is expected to be used early in the drug discovery process. read more

Cartesian Gridspeed, Ltd. announced the opening of its new sales, marketing and technical support subsidiary, SLIM Search, Inc. in Mission Viejo, California.
  SLIM Search, Inc. is marketing its SLIM Search genomic search tool to universities, government research, and research and development departments of biotechnology corporations and individual contributors. read more

The new Variant Reporter Software from Applied Biosystems automates detection of variants and streamlines data analysis process. The software uses proprietary algorithms to identify genetic variations based on standardized or user-defined parameters. Results are presented for validation in a visual format that allows researchers to simultaneously compare multiple quality control metrics. More information and a free trial version are available at: read more

More Products

We invite your comments and feedback for this edition of Biomarker Breakthroughs. Email us at maloryea@gmail.com
 

 

 

 

 

 

 

 

 

 

 

 


David Bailey of Chemoventures on: "Breakthroughs in Structure-Based Drug
Design: Implications for Drug Discovery and Development
"

This video presentation requires the Adobe Flash Player.
Click here
to download it if it is not currently installed on your computer.

 



New - Yihan Wang of ARIAD Pharmaceuticals, Inc.

Neil W Gibson of OSI Pharmaceuticals

Jeffrey Settleman Harvard Medical School and MGH Cancer Center

David Bailey of Chemoventures

N Claude Cohen of Synergix

-View All Webcasts

     
Cambridge Healthtech Institute 2007 - Your Life Science Network 
Cambridge Healthtech Institute | 250 First Avenue | Suite 300 | Needham, MA 02494 Phone: 781-972-5400 | Fax: 781-972-5425 | chi@healthtech.com